HROAX
Price
$12.19
Change
-$0.00 (-0.00%)
Updated
Jan 22 closing price
Net Assets
34.74M
MENCX
Price
$7.78
Change
-$0.05 (-0.64%)
Updated
Jan 22 closing price
Net Assets
227.06M
Ad is loading...

HROAX vs MENCX

Header iconHROAX vs MENCX Comparison
Open Charts HROAX vs MENCXBanner chart's image
M3Sixty Income and Opportunity A
Price$12.19
Change-$0.00 (-0.00%)
VolumeN/A
Net Assets34.74M
Madison Covered Call & Equity Income C
Price$7.78
Change-$0.05 (-0.64%)
VolumeN/A
Net Assets227.06M
HROAX vs MENCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
HROAX vs. MENCX commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROAX is a Hold and MENCX is a Buy.

Ad is loading...
FUNDAMENTALS
Fundamentals
MENCX has more cash in the bank: 227M vs. HROAX (34.7M). MENCX pays higher dividends than HROAX: MENCX (8.87) vs HROAX (0.00). HROAX was incepted earlier than MENCX: HROAX (9 years) vs MENCX (12 years). HROAX is a more actively managed with annual turnover of: 739.85 vs. MENCX (102.00). HROAX (1000) and MENCX (1000) have matching initial minimum investment requirements. HROAX annual gain was more profitable for investors over the last year : 17.21 vs. MENCX (5.80). MENCX return over 5 years is better than : 48.65 vs. HROAX (14.57).
HROAXMENCXHROAX / MENCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years12 years-
Gain YTD2.2651.294175%
Front LoadN/AN/A-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets34.7M227M15%
Annual Yield % from dividends0.008.87-
Returns for 1 year17.215.80297%
Returns for 3 years30.9318.83164%
Returns for 5 years14.5748.6530%
Returns for 10 yearsN/A52.93-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TVTX19.461.09
+5.93%
Travere Therapeutics
VRCA0.710.03
+5.12%
Verrica Pharmaceuticals
UBS35.101.06
+3.11%
UBS Group AG
MCB61.350.35
+0.57%
Metropolitan Bank Holding Corp
ITCI126.500.30
+0.24%
Intra-Cellular Therapies